Last reviewed · How we verify
PegLiposomal Doxorubicin
At a glance
| Generic name | PegLiposomal Doxorubicin |
|---|---|
| Also known as | Caelyx |
| Sponsor | AGO Study Group |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Pegliposomal Doxorubicin and 5-fluorouracil as Second Line Therapy for Metastatic Gastric Cancer (PHASE2)
- Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors (PHASE2)
- Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD) (PHASE1, PHASE2)
- Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PegLiposomal Doxorubicin CI brief — competitive landscape report
- PegLiposomal Doxorubicin updates RSS · CI watch RSS
- AGO Study Group portfolio CI